Axonics Modulation Technologies Inc (NASDAQ:AXNX) COO Rinda Sama sold 13,708 shares of Axonics Modulation Technologies stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $43.10, for a total value of $590,814.80. Following the completion of the sale, the chief operating officer now owns 171,293 shares of the company’s stock, valued at $7,382,728.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Rinda Sama also recently made the following trade(s):
- On Tuesday, July 21st, Rinda Sama sold 14,400 shares of Axonics Modulation Technologies stock. The stock was sold at an average price of $40.81, for a total value of $587,664.00.
- On Tuesday, May 19th, Rinda Sama sold 20 shares of Axonics Modulation Technologies stock. The stock was sold at an average price of $39.00, for a total value of $780.00.
NASDAQ AXNX opened at $42.36 on Friday. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -15.40 and a beta of 0.17. The stock’s 50 day moving average price is $38.21 and its two-hundred day moving average price is $33.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.31 and a current ratio of 10.28. Axonics Modulation Technologies Inc has a 52 week low of $15.25 and a 52 week high of $44.25.
Axonics Modulation Technologies (NASDAQ:AXNX) last released its earnings results on Tuesday, May 5th. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.17. The firm had revenue of $26.30 million for the quarter, compared to analysts’ expectations of $14.47 million. Axonics Modulation Technologies had a negative return on equity of 57.95% and a negative net margin of 208.60%. The business’s quarterly revenue was up 2341.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.47) EPS. On average, equities research analysts forecast that Axonics Modulation Technologies Inc will post -1.95 EPS for the current year.
AXNX has been the subject of several analyst reports. Piper Sandler restated a “buy” rating and set a $45.00 target price on shares of Axonics Modulation Technologies in a research report on Monday, July 27th. Needham & Company LLC restated a “buy” rating and set a $48.00 target price on shares of Axonics Modulation Technologies in a research report on Monday, July 13th. Zacks Investment Research cut Axonics Modulation Technologies from a “buy” rating to a “hold” rating in a report on Friday, June 5th. Morgan Stanley lifted their price objective on Axonics Modulation Technologies from $36.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, BidaskClub cut Axonics Modulation Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, July 15th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $43.40.
Several hedge funds have recently bought and sold shares of AXNX. Advisor Group Inc. grew its holdings in Axonics Modulation Technologies by 840.0% in the 4th quarter. Advisor Group Inc. now owns 940 shares of the company’s stock valued at $27,000 after buying an additional 840 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Axonics Modulation Technologies during the 4th quarter worth $28,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Axonics Modulation Technologies during the 2nd quarter worth $70,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Axonics Modulation Technologies in the first quarter valued at about $54,000. Finally, Victory Capital Management Inc. raised its position in Axonics Modulation Technologies by 23.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,947 shares of the company’s stock valued at $86,000 after purchasing an additional 555 shares during the last quarter. 66.50% of the stock is currently owned by institutional investors and hedge funds.
About Axonics Modulation Technologies
Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.
Featured Story: Why do company’s buyback their stock?
Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.